Last updated on October 2018

A Randomized Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients


Brief description of study

The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving HF symptoms and functional capacity in patients with heart failure with preserved ejection fraction (HFpEF).

Clinical Study Identifier: NCT03066804

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Shumen, Bulgaria
2.03miles
  Connect »